Stem cell therapy based on world-leading research
Delivered with EU-GMP certified cells and strict clinical oversight.
A new era of health.
We’re living longer, yet chronic and autoimmune conditions still dictate the rhythm of life for far too many. Mesenchymal stem cells offer a new potential path - calming inflammation, supporting repair, and activating healing in ways conventional treatments can’t.
Mesenchymal stem cells address the root drivers of chronic disease giving them potential far beyond any single condition.
In intravenous (IV) treatment, mesenchymal stem cells (MSCs) are delivered through an IV line, allowing them to circulate throughout the body and support systemic healing.
Administration:
IV infusion via a vein in the arm
Typical dose:
100 million MSCs
Eligibility:
Adults 25+, subject to medical assessment
Follow-up:
Video follow-ups at 1 and 6 months, with long-term monitoring
Price:
Starting from 27,500 USD
In intra-articular (IA) treatment, mesenchymal stem cells (MSCs) are injected directly into a joint, concentrating the treatment on a specific area.
Administration:
Ultrasound-guided injection into a joint
Typical dose:
50 million MSCs per joint
Eligibility:
Adults 18+
Follow-up:
Clinical follow-ups at 1, 3 and 6 months
Price:
Starting from 19,000 USD
Globally, we are shaping the next era of responsible stem cell therapy through aligned oversight and shared scientific standards.
"With GMP-certified allogeneic MSCs, for the first time we can provide patients with what autologous therapies lack: consistency and predictability"
Dr. Rikin Patel
Manufactured in Sweden.
Delivered worldwide.
Every Cellcolabs Clinical dose begins in our EU-GMP certified facility in Sweden and is safeguarded through GDP-regulated transport. Across all clinics, physicians follow one unified global protocol. The result is consistent quality and clinically responsible care wherever treatment is delivered.